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Abstract Ocular treatment of progressing proliferative
diabetic retinopathy is based on retinal laser photocoagula-
tion and pars plana vitrectomy. Improvements in instru-
mentation and advances in techniques and procedures have
increased indications for vitrectomy. These include vitreous
haemorrhage preventing laser photocoagulation, severe
nonclearing vitreous haemorrhage, subhyaloid and premac-
ular haemorrhage, tractional retinal detachment involving
or threatening the macula, combined tractional and rheg-
matogenous retinal detachment, progressive fibrovascular
proliferation, clinically significant macular oedema and
rubeosis iridis. Together with the increasing number of
indications, timing for vitrectomy has also changed. The
beneficial effect of early vitrectomy for these indications
has been clinically shown and supported by several studies.
The benefit is evident in case of type I diabetes and when
the duration of the diabetes is less than 20 years. Long-term
outcomes can therefore be improved when individualised
treatment algorithms are applied.
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Introduction
Diabetic retinopathy (DR) is one of the most common
causes of blindness among adults aged between 20 and
74 years and its prevalence continues to increase world-
wide [1]. The duration of the disease and the severity of
blood glucose fluctuations are major risk factors for the
development and progression of the DR [2]. Other risk
factors include the age of the patient, the type of diabetes,
elevated systemic blood pressure, clotting factors and renal
disease. During the first two decades of disease, nearly all
patients with type I diabetes and more than 60% of patients
with type II diabetes develop retinopathy [1].
Stages of DR
Diabetic retinopathy can be classified upon four stages:
1- Mild Nonpoliferative Retinopathy (NPDR). Minimal
vascular abnormalities, such as microaneurysms or
microhaemorrhages, are present.
2- Moderate Nonproliferative Retinopathy. Presence of
microaneurysms, haemorrhages and hard exudates. At
this stage closure of some retinal capillaries occurs,
leading to hypoxia. Infarction of the nerve fiber layer
leads to the formation of cotton-wool spots with
associated stasis in axoplasmic flow and retinal
oedema.
3- Severe Nonproliferative Retinopathy. As the disease
progresses, many vessels are closed thereby depriving
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blood supply to parts of the retina. These ischaemic
areas send signals to stimulate proliferation of new
blood vessels.
4- Proliferative Retinopathy (PDR). The signals for
nourishment, through the induction of angiogenic
growth factors, trigger the neovascularisation phenom-
enon along the retina and the vitreous gel. These new
vessels originating from the retina and/or the optic disk
can become leaky due to their fragility, leading to
preretinal or vitreous haemorrhages (Fig. 1). The
majority of the neovascular membranes are adherent
to the posterior vitreous cortex. When the posterior
hyaloid exerts traction, the edges of the neovascular
complex are pulled forwards, resulting in vitreous
haemorrhage. The accompanying fibrous tissue can
contract resulting in tractional or rhegmatogenous
retinal detachment. In the late stage, neovascular
glaucoma can result from new vessels growing on the
iris and anterior chamber structures.
Breakdown of the blood-retinal barrier as the attribute
of DR
The breakdown of the blood-retinal barrier with increased
permeability of the vessels results in leakage of fluid and
proteinaceous material, which clinically appears as retinal
thickening and exudates. Involvement of the fovea by
central retinal thickening and/or lipid deposits (hard
exudates) is named clinically significant macular oedema
(CSMO) and is the predominant cause of visual loss in DR
together with PDR [1].
Care and prevention of DR evolution
At present, glycaemic and blood pressure control remains
the standard systemic care to prevent and avoid the
evolution of DR. It has been demonstrated that strict
glycaemic control significantly reduces the risk of DR
development and progression in both types I and II diabetes
[3, 4]. Strict blood pressure control showed a highly
significant beneficial effect on the progression of DR and
visual loss [4, 5].
Several studies found that lipid-lowering drugs are able
to reduce hard exudates and inhibit the progression of DR
in patients with concomitant dyslipidemia [6, 7]. Oral
protein kinase C inhibitors were found to reduce visual loss
and the progression of CSMO [8]. Ocular treatment
includes laser retinal photocoagulation and vitrectomy.
Laser photocoagulation is indicated to ablate ischaemic
retinal areas, reducing the induction of neovascularisation.
Focal laser treatment at the posterior pole is indicated for
CSMO, trying to limit vascular leakage and thereby
preventing visual acuity deteriorations.
The current evidence suggests that intravitreal triamcin-
olone acetonide [9, 10] and antivascular endothelial growth
factor agents [11, 12] are effective adjunctive treatments to
laser photocoagulation or vitrectomy.
Pars plana vitrectomy
The goals of pars plana vitrectomy (PPV) are to remove the
vitreous gel, including the posterior hyaloid, and to relieve
tractions from the fibrovascular tissue. Although PPV may
have intraoperative and postoperative complications, in-
cluding cataract development, anterior hyaloidal fibrovas-
cular proliferation, fibrovascular ingrowth, recurrent
vitreous haemorrhage, retinal detachment and endophthal-
mitis, it has various indications in the treatment of RD.Fig. 1 PPV for vitreous haemorrhage
Fig. 2 Vitreous and preretinal haemorrhage from bleeding new
vessels
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In the recent years further development in vitrectors
technology and other instrumentations (e.g., small gauge
vitrectomy systems, endolaser and optic fibers, the use of
perfluorocarbonades and tamponating agents) together with
the refinements of techniques have improved the safety and
efficacy of PPV thereby expanding its indications in the
treatment of DR. PPV was once reserved only for massive
persisting vitreous haemorrhage or retinal detachment.
At present, the most common indications for PPV
include: vitreous haemorrhage preventing laser photoco-
agulation, severe nonclearing vitreous haemorrhage
(Fig. 2), subhyaloid and premacular haemorrhage, trac-
tional retinal detachment involving or threatening the
macula, combined tractional and rhegmatogenous retinal
detachment, progressive fibrovascular proliferation,
CSMO and rubeosis iridis [13].
Timing of PPV
The improved safety of PPV has not only increased the
indications to perform it, but also changed its timing.
Vitreous haemorrhage tends to spontaneously resolve in
about 20% of patients and in 13% of type I diabetes;
nonetheless, recurrences are frequently observed. Beyond
severity and duration, the open issue has therefore become
a timing indication.
In the Diabetic Retinopathy Vitrectomy Study (DRVS)
616 eyes with recent severe vitreous haemorrhage reducing
visual acuity to 5/200 or less for at least 1 month were
randomly assigned to either early vitrectomy or deferral of
vitrectomy for 1 year [14]. Patients were classified as
having type I or type II diabetes and the duration of
diabetes. The 4-year results indicate that visual acuity
recovery was more frequent with early vitrectomy in type I
diabetes patients compared with deferred vitrectomy. This
recovery was greater when the duration of diabetes was less
than 20 years. No significant final clinical advantage was
appreciated if early vitrectomy was performed in the mixed
or type II diabetes. This difference in treatment effects by
diabetes type and duration was generally statistically
significant for the 10/20 or better visual acuity outcome.
This result was achieved in 25% of the early-treatment
patients and in 15% of the deferral group. Other character-
istics as the type of vitreous haemorrhage, its duration, the
history of retinal photocoagulation and the initial visual
acuity did not have a statistically significant influence on
the result. In the type I diabetes groups retinal detachment
occurred considerably less often when early vitrectomy was
performed. In the type II diabetes groups there was no
statistically significant difference in its frequency between
early or deferred vitrectomy groups.
The Authors of the DRVS explain the reason why
performing early vitrectomy brings benefits in type I
diabetes only and not in type II asserting that in type I
diabetes the DR has more aggressive characteristics,
particularly when the duration of the disease is less than
20 years. The more aggressive progression of neovascular-
isation, of fibrous proliferation contraction and of vitreor-
etinal tractions in type I diabetes explain the fact that
deferring PPV by 1 year results in worsening of DR with
consequent reduced visual acuity recovery after surgery.
Other studies have concluded that early vitrectomy for eyes
with recent extensive preretinal haemorrhage, retinal trac-
tion and tractional detachment [15] and for progressive
PDR [16] is preferable even in type II diabetes.
Prompt PPV is also indicated for dense premacular
haemorrhage. Another review has demonstrated that
patients who received PPV within 1 month from the
haemorrhage achieved better final visual acuity. None of
these patients developed significant macular traction, while
patients who did not receive PPV within 4 weeks all
progressed to late macular traction [17].
Further indications for early PPV come from a study
that compared early versus deferred PPV for PDR with
dense subhyaloid haemorrhage and significant visual
acuity loss. The results show an improved anatomic
success rate (85% versus 73% of the deferral group) and
a higher rate of reading visual capability (54% versus
18% of the deferral group) thereby suggesting that early
PPV is preferable [18].
Conclusions
At present PPV in the treatment of PDR is indicated for
eyes with vitreous haemorrhage preventing laser photoco-
agulation, severe nonclearing vitreous haemorrhage, sub-
hyaloid and premacular haemorrhage (of at least 1 month
duration), tractional retinal detachment involving or threat-
ening the macula, combined tractional and rhegmatogenous
retinal detachment, progressive fibrovascular proliferation
despite panretinal laser photocoagulation and CSMO. It has
been demonstrated that early versus deferred vitrectomy
brings clinically significant beneficial effects in case of type
I diabetes with a duration of less than 20 years.
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